Talks with Pfizer are on: AIIMS director Dr. Randeep Guleria
Talks with Pfizer are on: AIIMS director Dr. Randeep Guleria
Share:

Discussions are on between the Indian government and pharmaceutical company Pfizer for the expected collaboration in procuring the Pfizer's vaccine, said Director of All India Institute of Medical Sciences Dr. Randeep Guleria at the Hindustan Times Leadership Summit.

The vaccine developed by Pfizer in collaboration with Germany’s BioNTech has exhibited about 95% effectiveness against COVID-19 in the final stage of clinical trials but has to be stored at a super cool temperature of about (-)70 degrees Celsius.

India currently lacks infrastructure for the storage of vaccines at such low temperatures. Currently, clinical trials for an effective vaccine for the Indian population are being carried out by Serum Institute of India, Cadila Healthcare Ltd, Bharat Biotech International Ltd, Reliance Life Sciences Pvt Ltd, Aurobindo Pharma Ltd, Gennova Biopharmaceuticals Ltd and Biological E Ltd.

Additionally, Dr. Reddy's Laboratories has entered into an agreement with the Russian Direct Investment Fund to conduct trials of the Sputnik vaccine for distribution in India. Russian authorities have claimed that the vaccine is 92% effective against COVID-19. Guleria emphasized that by end of next year, at least 30-40% of the people will need to be vaccinated; of them, the first priority will be given to health care workers and the elderly.

Rich countries books corona vaccine before arrival, WHO says, 'Vaccine nationalism will not reduce this epidemic'

'Life will be normal till next year' claims Scientist who made '90% successful vaccine'

COVID-vaccine: Healthcare workers, elderly to get priority: Harsh Vardhan

Join NewsTrack Whatsapp group
Related News